P206 Identification of novel senolytic candidates for the treatment of chronic respiratory diseases with accelerating aging
Year: 2023
Type: conference-abstract
Abstract: Background Cellular senescence is a process that induces cells into a state of irreversible replicative arrest, whereby they are apoptosis-resistant, and release inflammatory mediators known as the senescence-associated secretory phenotype (SASP). Cellular senescence and the SASP potentially have a significant influence on the process of ageing and pathologies of accelerated premature-aging related chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Senolytic agents, capable of selectively killing senescent cells by inducing apoptosis, could potentially have major implications for treating the senescence-driven accelerated ageing pathology found in COPD and IPF. The aim of this project is to identify a new class of senolytic agents. Methods Compounds (0.1 and 10µM) from an FDA-approved chemical library (700 compounds) were treated 2 days after etoposide (1µM)-treated or untreated airway epithelial cells, BEAS-2B. The resazurin cell viability assay was conducted 2-days post-treatment and the ability of the compounds to eliminate senescent cells was assessed. Positive candidates were treated in double hit etoposide senescent BEAS-2B. Senescence markers p21WAF1/CIP1 and p16INK4A expression (western blotting) and positive Senescence-Associated-b-Galactosidase (SA-β-Gal) staining were assessed. SASP marker PAI (Plasminogen Activator Inhibitor)-1 was detected in supernatant using ELISA. Results Single treatment with etoposide was confirmed to induce cellular senescence characterized by an increase in SA-β-Gal staining, p16INK4A and p21WAF1/CIP1 expression. After high throughput screening with this cell model, we identified 6 candidates to be able to eliminate senescent cells, but not healthy cells. Further validation revealed that Dipyridamole (DP) showed decrease in p21WAF1/CIP1 expression by 20.5% compared to etoposide control (p>0.05, n=4), where a well-established senolytic cocktail (a combination of Dasatinib and Quercetin) reduced p21WAF1/CIP1 by 27.6%. DP and Amlodipine (AL) also reduced the proportion of SA-b-Gal positive cells by 15.5% and 31.5%, respectively, compared to etoposide control. Etoposide-induced PAI-1 release was also reduced by those candidates (p>0.05) as well as DQ (57.0% reduction). Conclusion DP and AL showed some potentials as senolytic agents. Further studies using primary cells obtained from patients with COPD or IPF are needed for full validation.
Source: Thorax
Authors: P Gomes, A Rimbert, S Hassibi, J Baker, K Ito
Institution: Imperial College London
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4388410635
